The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing) on Vaginal Innate and Inflammatory Biomarkers.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Ethinylestradiol/etonogestrel (Primary)
- Indications Bacterial vaginosis
- Focus Biomarker; Pharmacodynamics
- 23 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 11 Oct 2011 New trial record